Asia Pacific RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

The Asia Pacific RNA Based Therapeutic Market is expected to witness market growth of 15.6% CAGR during the forecast period (2021-2027).

RNA-based biopharmaceuticals, which include vaccines and treatments, are a relatively new class of medicine. These biopharmaceuticals are preventive medicines that are used to treat a variety of rare and chronic diseases, such as cardiovascular disease, TB, diabetes, and cancer. The primary goal of RNA therapies is to develop an effective treatment for rare diseases and other unmet medical needs. This is a research-based area, and technological advancements are expected to increase the global RNA-based medicines and vaccines market during the forecasting period.

In addition, in upcoming years, the development of numerous potential technologies such as RNA interference technology, SMaRT technology, and antisense technology is anticipated to offer significant growth possibilities for the worldwide RNA-based therapies and vaccines market.

The market for RNA-based therapeutics and vaccines in Japan is the largest in the Asia Pacific, owing to the growing importance of customized medicine. In addition, the high frequency of infectious diseases in the Asia Pacific is likely to create significant potential for RNA-based therapeutics and vaccines. The rising population of the countries that comes under APAC such as India and China, plays a major role in accelerating the demand for RNA-based therapeutic across APAC.

In addition, these countries are under a developing phase and going under constant enhancements and developments rapidly. With these developments, the healthcare infrastructure of the region is constantly growing stronger.

The China market dominated the Asia Pacific RNA Based Therapeutic Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $685.8 million by 2027. The Japan market is exhibiting a CAGR of 15% during (2021 - 2027). Additionally, The India market is expected to witness CAGR of 16.4% during (2021 - 2027).

Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• RNA Antisense
• RNA Interference (RNAi)

By Application

• Genetic disorders
• Auto immune disorders

By End User

• Research Institutes
• Hospitals & Clinics

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma, Inc.
• Alnylam Pharmaceuticals, Inc.
• Sanofi S.A. (Sanofi Genzyme)
• Biogen, Inc.
• Gradalis, Inc.
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Silence Therapeutics Plc

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free